Dashboard
Manage Tickers

AVIR


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

atea-pharma-to-present-new-data-supporting-combination-regimen-of-bemnifosbuvir-as-potential-for-hcv-infection-treatment-at-the-liver-meeting-2025-aasld
Atea Pharma To Present New Data Supporting...
10/07/2025 12:06:56

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery...

atea-pharmaceuticals-q2-eps-044-misses-043-estimate
Atea Pharmaceuticals Q2 EPS $(0.44) Misses...
08/07/2025 20:10:56

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate o...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

atea-begins-global-late-stage-trial-of-oral-hepatitis-c-drug-combo-aimed-at-easier-faster-cure
Atea Begins Global Late-Stage Trial of Ora...
06/24/2025 11:07:19

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery...

atea-pharmaceuticals-q1-eps-040-beats-041-estimate
Atea Pharmaceuticals Q1 EPS $(0.40) Beats ...
05/12/2025 20:15:30

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of ...

atea-pharmaceuticals-releases-full-results-from-phase-2-study-of-regimen-of-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus-including-confirmed-98-sustained-virologic-response-at-12-weeks-post-treatment-after-short-8-week-treatment-duration-for-regimen
Atea Pharmaceuticals Releases Full Results...
05/07/2025 11:13:23

 Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-We...

atea-pharma-presents-results-from-full-cohort-of-patients-enrolled-in-phase-2-study-evaluating-once-daily-combination-of-bem-and-rzr-for-treatment-of-hepatitis-c-virus
Atea Pharma Presents Results From Full Coh...
05/07/2025 11:04:01

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Wee...

atea-pharmaceuticals-set-to-present-top-poster-on-bemnifosbuvir-and-ruzasvir-potential-best-in-class-hepatitis-c-therapy-at-easl-202
Atea Pharmaceuticals Set To Present Top Po...
04/23/2025 11:08:05

atea-pharmaceuticals-board-authorizes-repurchase-of-up-to-25m-of-common-stock
Atea Pharmaceuticals Board authorizes Repu...
04/17/2025 11:06:19

morgan-stanley-maintains-equal-weight-on-atea-pharmaceuticals-lowers-price-target-to-6
Morgan Stanley Maintains Equal-Weight on A...
04/11/2025 15:28:33

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the pric...

atea-pharmaceuticals-announces-dosing-of-first-patient-in-c-beyond-phase-3-study-evaluating-regimen-of-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus-says-new-next-generation-hcv-therapies-needed-to-improve-patient-outcomes
Atea Pharmaceuticals Announces Dosing Of F...
04/09/2025 11:05:54

atea-pharmaceuticals-announced-the-poster-presentation-of-bemnifosbuvir-preclinical-data-at-the-38th-international-conference-on-antiviral-research-2025-taking-place-march-17-21-2025-in-las-vegas-nevada
Atea Pharmaceuticals Announced The Poster ...
03/19/2025 11:01:53

atea-pharma-cuts-workforce-by-25-expects-15-million-in-cost-savings-plans-phase-3-hepatitis-c-trial
Atea Pharma Cuts Workforce By 25%, Expects...
03/07/2025 19:43:21

Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing an...

atea-pharmaceuticals-q4-eps-040-misses-037-estimate
Atea Pharmaceuticals Q4 EPS $(0.40) Misses...
03/06/2025 21:15:21

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate o...

earnings-scheduled-for-march-6-2025
Earnings Scheduled For March 6, 2025
03/06/2025 08:32:20

atea-pharmaceuticals-reports-its-cash-cash-equivalents-and-marketable-securities-balance-of-4547m-at-december-31-2024-and-a-cash-runway-anticipated-into-2028
Atea Pharmaceuticals Reports Its Cash, Cas...
01/13/2025 12:19:52

Global Phase 3 HCV Program Expected to Initiate in 1Q 2025Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen S...

atea-pharmaceuticals-has-engaged-evercore-investment-bank-to-identify-potential-opportunities-including-the-exploration-of-strategic-partnerships-related-to-its-phase-3-ready-program-for-hepatitis-c-virus
Atea Pharmaceuticals Has Engaged Evercore ...
12/16/2024 10:01:56

after-failed-covid-19-drug-trial-atea-pharmaceuticals-touts-encouraging-data-from-mid-stage-hepatitis-c-study
After Failed COVID-19 Drug Trial, Atea Pha...
12/04/2024 20:14:18

Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuv...

atea-pharmaceuticals-announced-that-the-companys-phase-2-study-of-the-regimen-of-bemnifosbuvir-a-nucleotide-analog-polymerase-inhibitor-and-ruzasvir-an-ns5a-inhibitor-for-treatment-of-hepatitis-c-virus-met-its-primary-endpoints-of-safety-and-sustained-virologic-response-at-12-weeks-post-treatment
Atea Pharmaceuticals Announced That The Co...
12/04/2024 12:02:37

atea-pharmaceuticals-unveils-new-data-supporting-bemnifosbuvir-and-ruzasvir-combination-for-hepatitis-c-treatment-at-aaslds-liver-meeting-2024-phase-2-findings-highlight-potential-efficacy
Atea Pharmaceuticals Unveils New Data Supp...
11/15/2024 16:02:12

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION